Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT06831253
Recruiting Not applicable

Efficacy of Platelet-Rich Plasma Injection in Dry Eye Syndrome

NCT06831253 · tracked via the Priya Life Science France tracker
Sponsor
Centre Hospitalier Universitaire de Nice
Phase
Not applicable
Started
2025-03-17
Last updated
2025-03-19

Condition(s) studied

Severe Dry Eye SyndromesDry Eye Syndromes

Investigational drug(s) / intervention(s)

injections of Platelet-Rich Plasma in lacrimal gland

injections of Platelet-Rich Plasma in lacrimal gland: injections of Platelet-Rich Plasma in lacrimal gland

Study summary

The investigatror wants to show the efficacy of Platelet-Rich Plasma injection in lacrimal gland to restore the lacrimal secretion in patients presenting aqueous deficiency reponsible for severe dry eye syndrome.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Platelet counts, and clotting factors in the standarts * Presenting with severe dry keratoconjunctivitis diagnosed by an ophthalmologist Exclusion Criteria: * Patients with significant fibrosis of the conjunctival portion of the lacrimal gland * Patients with complete stenosis of both lacrimal meatus in the treated eye

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
CHU de Nice Nice Site Principal Investigator Recruiting

More Centre Hospitalier Universitaire de Nice trials in France

Impact of an e-Bug Educational Intervention on HPV Vaccine Uptake in Middle School Students Recruiting
The Benefits of Posterior Joint Infiltration in Chronic Low Back Pain Starting soon
QUANTACT : Impact of Pangenomic QUANTitative Alterations in Cancer Therapy Enrolling by invitation
Study of the Effectiveness of Transcranial Direct Current Stimulation on Obsessive Compulsive Disorder Active, not recruiting
Mediterranean Visceral Leishmaniasis With Leishmania Infantum Active, not recruiting

Other trials for the same condition

Three-dimensional Analysis of EMMPRIN on Conjunctival Epithelial Cells Surface in Severe Dry Eye Syndrome (ALTESSE) Recruiting
3 Month Study of Alocross Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or Keratoconjunctivitis Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06831253 on ClinicalTrials.gov ↗ ← All trials in France